

SEQUANA MEDICAL

Limited Liability Company

Registered office: AA Tower, Technologiemark 122, 9052 Ghent, Belgium
VAT BE 0707.821.866 Register of Legal Entities Ghent, section Ghent

<p style="text-align: center;">INVITATION ORDINARY AND EXTRAORDINARY GENERAL SHAREHOLDERS' MEETINGS to be held on Thursday, 27 May 2021, at 9:00 a.m. (Belgian time)</p>
--

The holders of securities issued by Sequana Medical NV (the "**Company**") are invited to the ordinary general shareholders' meeting of the Company. After the agenda of the ordinary general shareholders' meeting has been treated, the meeting will be shortly suspended in order to be continued as an extraordinary general shareholders' meeting before a notary public.

GENERAL INFORMATION

Date, hour and venue: The ordinary and extraordinary general shareholders' meetings will be held on Thursday, 27 May 2021 at 9:00 a.m. (Belgian time), at AA Tower, Technologiemark 122, 9052 Ghent, Belgium, or at such other place as will be indicated at that place at that time. There is no attendance quorum requirement for the ordinary general shareholders' meeting. There is, however, an attendance quorum requirement for the items on the agenda of the extraordinary general shareholders' meeting (see also below under "*—Extraordinary General Shareholders' Meeting*"). If the attendance quorum for the items on the agenda of the extraordinary general shareholders' meeting were not to be reached, a second extraordinary general shareholders' meeting will be held for these items on Wednesday, 23 June 2021, unless, as the case may be, decided otherwise on behalf of the Board of Directors.

Exceptional circumstances: In light of the COVID-19 pandemic, it is currently envisaged that the measures imposed by the Belgian government to deal with this pandemic, such as the limitations on the number of people attending gatherings and the obligation to guarantee a distance of 1.5 meters between each person, may still be in effect on Thursday, 27 May 2021, the date of the Company's ordinary and extraordinary general shareholders' meetings. These measures are in the interest of the health of individual securities holders, as well as of the members of the personnel of the Company and others who are responsible for organizing the general shareholders' meetings. Furthermore, it cannot be excluded that the Belgian government will impose additional measures. Hence, the Company recommends that the shareholders of the Company that wish to participate to the general shareholders' meetings make use, as much as practically possible, of the right to vote through voting by mail or by means of a written proxy to the Chairman of the Board of Directors. The Company will grant access to the meeting to holders of securities, proxy holders and other persons only to the extent permitted in light of the measures taken or to be taken by the authorities as applicable on the date of the meeting, and always taking into account the recommendations of the authorities, and safety and health considerations. Moreover, holders of securities of the Company are encouraged to exercise their right to ask questions related to the items on the agenda of the general shareholders' meeting in writing. For more information regarding the modalities of the aforementioned ways to participate in the ordinary and extraordinary general shareholders' meetings, please see below under "*—Participation to the meetings*". The Company will monitor the situation and applicable measures closely, and may provide further updates that are relevant or have an impact on the general shareholders' meetings on its website (www.sequanamedical.com).

Opening of the doors: In order to facilitate the keeping of the attendance list on the day of the ordinary and extraordinary general shareholders' meetings, holders of securities and their representatives are invited to register as of 8:15 a.m (Belgian time).

ORDINARY GENERAL SHAREHOLDERS' MEETING

Agenda and proposed resolutions: The agenda and the proposed resolutions of the ordinary general shareholders' meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the Board of Directors, are as follows:

1. Reports on the statutory financial statements

Submission of, and discussion on, the annual report of the Board of Directors and the report of the Statutory Auditor on the statutory financial statements for the financial year ended on 31 December 2020.

2. Approval of the statutory financial statements

Approval of the statutory financial statements for the financial year ended on 31 December 2020, and of the allocation of the result as proposed by the Board of Directors.

Proposed resolution: The general shareholders' meeting approves the statutory financial statements for the financial year ended on 31 December 2020, as well as the allocation of the result as proposed by the Board of Directors.

3. Consolidated financial statements

Submission of, and discussion on, the consolidated financial statements for the financial year ended on 31 December 2020.

4. Reports on the consolidated financial statements

Submission of, and discussion on, the annual report of the Board of Directors and the report of the Statutory Auditor on the consolidated financial statements for the financial year ended on 31 December 2020.

5. Discharge from liability of the Directors

Discharge from liability of the Directors for the exercise of their mandates during the financial year ended on 31 December 2020.

Proposed resolution: The general shareholders' meeting grants discharge from liability to each of the Directors who was in office during the financial year ended on 31 December 2020, for the performance of its, his or her mandate during that financial year.

6. Discharge from liability of the Statutory Auditor

Discharge from liability of the Statutory Auditor for the exercise of its mandate during the financial year ended on 31 December 2020.

Proposed resolution: The general shareholders' meeting grants discharge from liability to the Statutory Auditor which was in office during the previous financial year, for the performance of its mandate during that financial year.

7. Remuneration report

Submission of, discussion on, and approval of the remuneration report prepared by the Remuneration and Nomination Committee, and included in the annual report of the Board of Directors for the financial year ended on 31 December 2020.

Proposed resolution: The general shareholders' meeting approves the remuneration report included in the annual report of the Board of Directors for the financial year ended on 31 December 2020.

8. Remuneration Policy

Submission of, discussion on, and approval of the remuneration policy prepared by the Remuneration and Nomination Committee and approved by the Board of Directors.

Proposed resolution: The general shareholders' approves the remuneration policy.

9. Re-appointment of directors

Taking into account the recommendation of the Remuneration and Nomination Committee, the Board of Directors recommends that (a) Ian Crosbie, (b) Pierre Chauvineau, (c) WIOT BV, with Wim Ottevaere as permanent representative, (d) Rudy Dekeyser, and (e) Erik Amble, are re-appointed as members of the Board of Directors, each for a term of four years.

For further information regarding these Directors, reference is made to the corporate governance statement included in the annual report of the Board of Directors on the consolidated financial statements of the Company for the financial year ended on 31 December 2020.

Based on information made available by respectively Pierre Chauvineau and WIOT BV, with Wim Ottevaere as permanent representative, it appears that Pierre Chauvineau, and each of WIOT BV and Wim Ottevaere, satisfy the applicable requirements in order to be nominated and appointed as independent Directors in accordance with Article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code.

Proposed resolutions:

- (a) The general shareholders' meeting resolves to re-appoint Ian Crosbie as Director of the Company for a term of four years, up to and including the closing of the ordinary general shareholders' meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. While Ian Crosbie's mandate as Chief Executive Officer shall be remunerated, his mandate as director shall not be remunerated.
- (b) The general shareholders' meeting resolves to re-appoint Pierre Chauvineau as independent Director of the Company within the meaning of Article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of four years, up to and including the closing of the ordinary general shareholders' meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the Director is as decided by the extraordinary general shareholders' meeting held on 18 January 2019 (which decision entered into force on 12 February 2019).
- (c) The general shareholders' meeting resolves to re-appoint WIOT BV, with Wim Ottevaere as permanent representative, as independent Director of the Company within the meaning of Article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of four years, up to and including the closing of the ordinary general shareholders' meeting to be held in 2025 which will have decided upon the financial statements for the

financial year ended on 31 December 2024. The remuneration of the Director is as decided by the extraordinary general shareholders' meeting held on 18 January 2019 (which decision entered into force on 12 February 2019).

- (d) The general shareholders' meeting resolves to re-appoint Rudy Dekeyser as Director of the Company for a term of four years, up to and including the closing of the ordinary general shareholders' meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the Director is as decided by the extraordinary general shareholders' meeting held on 18 January 2019 (which decision entered into force on 12 February 2019).
- (e) The general shareholders' meeting resolves to re-appoint Erik Amble as Director of the Company for a term of four years, up to and including the closing of the ordinary general shareholders' meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the Director is as decided by the extraordinary general shareholders' meeting held on 18 January 2019 (which decision entered into force on 12 February 2019).

Note: If the proposed resolutions set out in point 9 are approved by the general shareholders' meeting, the Company's Board of Directors will be composed of (1) Ian Crosbie, Chief Executive Officer (CEO), executive Director and managing Director (until 2025), (2) Pierre Chauvineau, independent Director and chairperson of the Board of Directors (until 2025), (3) WIOT BV, with Wim Ottevaere as permanent representative, independent Director (until 2025), (4) Rudy Dekeyser, non-executive Director (until 2025), (5) Erik Amble, non-executive Director (until 2025), and (6) Jason Hannon, independent Director (until 2022).

10. Re-appointment of Statutory Auditor

Proposed resolution: Upon recommendation of the Company's Audit Committee, and in line with the Audit Committee's preference, the general shareholders' meeting resolves: (i) to re-appoint PwC Bedrijfsrevisoren BV, with registered office at Woluwe Garden, Woluwedal 18, 1932 Sint-Stevens-Woluwe, Belgium, represented by Mr. Peter D'hondt, as Statutory Auditor of the Company, for a period of three years up to and including the closing of the ordinary general shareholders' meeting to be held in 2024 which will have decided upon the financial statements for the financial year ended on 31 December 2023, and (ii) to determine the annual remuneration of the Statutory Auditor at EUR 64,900.00 for the audit of the statutory and the consolidated accounts of the Sequana Medical group. This amount is exclusive of sundry expenses, IBR-IRE contribution and VAT, and is subject to an annual indexation as from 2022.

11. Approvals in accordance with Article 7:151 of the Belgian Companies and Associations Code

In July 2020, the Company entered into subordinated loan agreements with PMV/z-Leningen NV ("**PMV/z**"), Sensinnovat BV ("**Sensinnovat**") and Belfius Insurance NV ("**Belfius**"), for an aggregate principal amount of EUR 7.3 million, of which loans for a principal amount of EUR 1.4 million could be converted by the relevant lenders for new shares of the Company in the event of a future equity financing or sale of the Company and this by means of a contribution in kind of the respective payables due by the Company (whether as principal amount or as interest) into the share capital of the Company. On the date hereof, the following of the aforementioned subordinated loan agreements are still in force (the "**Loan Agreements**"):

- (a) Loan agreement of 27 July 2020 between the Company and Belfius for an aggregate principal amount of EUR 2,000,000.00 (non-convertible) and an interest component of 6% per year;
- (b) Loan agreement of 17 July 2020 between the Company and Sensinnovat for an aggregate principal amount of EUR 400,000.00 (non-convertible) and an interest component of 6% per year;
- (c) Convertible loan agreement of 17 July 2020 between the Company and PMV/z for an aggregate principal amount of EUR 800,000.00 (convertible) and an interest component of 5% per year; and
- (d) Addendum to the abovementioned convertible loan agreement of 17 July 2020 between the Company and PMV/z for an additional aggregate principal amount between EUR 2,500,000.00 and EUR 3,500,000.00 (non-convertible), and an interest component of 6% per year.

The Loan Agreements have a term of 36 months, and are repayable in full upon expiry of the term. Each of the abovementioned Loan Agreements provide that upon the occurrence of a "change of control" (as described below), the relevant lender may declare the relevant loan to be due and payable, together with accrued interest thereon and any other sums then owed by the Company thereunder. In this context, "change of control" means the holders of shares in the Company at the date of the relevant Loan Agreement ceasing to directly or indirectly control the Company; whereby "control" means the power to: (a) cast, or control the casting of, more than one-half of the maximum number of votes that might be cast at the shareholders' meeting of the Company; (b) appoint or remove all, or the majority of, the Directors of the Company; or (c) give directions with respect to the operating and financial policies of the Company. For more information on the abovementioned Loan Agreements, reference is made to annual report of the Board of Directors on the consolidated financial statements for the financial year ended on 31 December 2020.

Proposed resolution: The general shareholders' meeting takes note of, approves and ratifies in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses in the Loan Agreements, which fall or could be considered to fall within the scope of Article 7:751 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting also grants a special power of attorney to each Director of the Company, to notary public Dirk Delbaere, and to Fin-2K BV, represented by Kirsten Van Bockstaele (*Chief Financial Officer*) (each a "**Proxy Holder**"), each Proxy Holder acting singly and with the right of substitution, to complete the formalities required by Article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.

No attendance quorum: There is no attendance quorum requirement for the deliberation and voting on the agenda items referred to in the aforementioned agenda of the ordinary general shareholders' meeting.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned agenda of the ordinary general shareholders' meeting shall be passed if they are approved by a simple majority of the votes validly cast by the shareholders. Pursuant to Article 7:135 of the

Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the ordinary general shareholders' meeting, but only with an advisory vote.

EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING

Agenda and proposed resolution: The agenda and proposed resolutions of the extraordinary general shareholders' meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the Board of Directors, are as follows:

1. Submission of the special report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital

Consideration, discussion and submission of the special report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the Board of Directors under the authorised capital, as set out below in item 2 of the agenda of the extraordinary general shareholders' meeting, and setting out the specific circumstances in which the Board of Directors will be able to use its powers under the authorised capital, and the purposes that it should pursue.

2. Renewal of the authorisation to the Board of Directors to increase the share capital within the framework of the authorised capital

Proposed resolution: The extraordinary general shareholders' meeting resolves to renew the authorisation to the Board of Directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set forth in the special report of the Board of Directors prepared in accordance with Article 7:199 of the Belgian Companies and Associations Code, as referred to in agenda item 1 of this extraordinary general shareholders' meeting. Consequently, the extraordinary general shareholders' meeting resolves to delete Article 8 "Authorised capital" of the Articles of Association of the Company entirely and to replace it with the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders' meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company's share capital at the time of the general shareholders' meeting approving the authorised capital):

"8. AUTHORISED CAPITAL

The board of directors is authorised to increase the share capital of the company on one or several occasions by a maximum aggregate amount of [100% of the company's share capital at the time of the adoption of the new authorised capital].

The board of directors may increase the share capital by contributions in cash or in kind, by capitalisation of reserves, whether available or unavailable for distribution, and capitalisation of issue premiums, with or without the issuance of new shares, with or without voting rights, that will have the rights as will be determined by the board of directors. The board of directors is also authorised to use this authorisation for the issuance of convertible bonds or subscription rights, bonds with subscription rights or other securities.

This authorisation is valid for a period of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutes of the extraordinary general shareholders' meeting of the company held on [date of the general shareholders' meeting approving the renewed authorised capital].

In the event of a capital increase decided by the board of directors within the framework of the authorised capital, all issue premiums booked, if any, will be accounted for in accordance with the provisions of these articles of association.

The board of directors is authorised, when exercising its powers within the framework of the authorised capital, to restrict or cancel, in the interest of the company, the preferential subscription rights of the shareholders. This restriction or cancellation of the preferential subscription rights can also be done in favour of members of the personnel of the company or of its subsidiaries, or in favour of one or more persons other than members of the personnel of the company or of its subsidiaries.

The board of directors is authorised, with the right of substitution, to amend the articles of association, after each capital increase that has occurred within the framework of the authorised capital, in order to bring them in conformity with the new situation of the share capital and the shares."

3. Submission of reports in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code relating to the proposal to issue 1,000,000 new 2021 Share Options

Consideration, discussion and submission of:

- (a) the report of the Board of Directors of the Company in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 1,000,000 new subscription rights for shares of the Company (the "**2021 Share Options**"), pursuant to a share option plan named "the 2021 Share Option Plan", and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of Article 1:27 of the Belgian Companies and Associations Code (the "**Selected Participants**"); and
- (b) the report of the Statutory Auditor of the Company in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 1,000,000 2021 Share Options, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants.

4. Proposal to issue 2021 Share Options

Proposed resolution: The extraordinary general shareholders' meeting resolves to approve the issuance of 1,000,000 2021 Share Options, pursuant to a share option plan named the "2021 Share Option Plan", and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants. In view thereof, the general shareholders' meeting resolves as follows:

- (a) Terms and conditions of the 2021 Share Options: The terms and conditions of the 2021 Share Options (including, but not limited to, the exercise price of the 2021 Share Options) shall be as set out in the annex to the report of the Board of Directors referred to in point 3(a) of the agenda (for the purpose of this resolution, the "**Plan**"), a copy of which shall remain attached to the minutes reflecting the present resolution. The 2021 Share Options have a term of ten years as from their issue date;
- (b) Underlying shares: Each 2021 Share Option shall entitle the holder thereof to subscribe for one (1) new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2021 Share Options shall have the same rights and benefits as, and rank *pari passu* in all respects, including as to entitlements

to dividends and distributions, with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and distributions in respect of which the relevant record date or due date falls on or after the date of issue of the shares;

- (c) Disapplication of the preferential subscription right to the benefit of the Selected Participants: The general shareholders' meeting resolves, in accordance with Article 7:191 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants (being the members of the personnel of the Company and its subsidiaries from time to time), and to approve the possibility for the Company to grant the 2021 Share Options to the Selected Participants, as further explained in the report of the Board of Directors referred to in point 3(a) of the agenda and the terms and conditions of the Plan;
- (d) Confirmation of the subscription of 2021 Share Options by the Company: The general shareholders' meeting resolves to approve and confirm that the Company will be able to subscribe for the 2021 Share Options, with a view to creating a pool of outstanding 2021 Share Options available for further grants to Selected Participants. The Company may not, however, exercise the 2021 Share Options for its own account;
- (e) Conditional capital increase and issue of new shares: The general shareholders' meeting resolves, subject to, and to the extent of the exercise of 2021 Share Options, to increase the Company's share capital and to issue the relevant number of new shares issuable upon the exercise of the 2021 Share Options. Subject to, and in accordance with the provisions of the Plan, upon exercise of the 2021 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2021 Share Options will be allocated to the share capital of the Company. To the extent that the amount of the exercise price of the 2021 Share Options, per share to be issued upon exercise of the 2021 Share Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise of the 2021 Share Options, equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction of the share capital of the Company;
- (f) Issue premium: Any issue premium that will be booked in connection with the 2021 Share Options shall be accounted for on a non-distributable account on the liabilities side of the Company's balance sheet under its net equity, and the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general shareholders' meeting passed in the manner required for an amendments to the Company's Articles of Association;
- (g) Powers of attorney: The Board of Directors is authorised to implement and execute the resolutions passed by the general shareholders' meeting in connection with the 2021 Share Options, and to take all steps and carry out all formalities that shall be required by virtue of the Plan, the Company's Articles of Association and applicable law in order to issue or transfer the shares upon exercise of the 2021 Share Options. Furthermore, each Director of the Company, and each member of the executive management of the Company, each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power,

upon exercise of the 2021 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company's Articles of Association in order to reflect the new share capital and number of outstanding shares following the exercise of the 2021 Share Options, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2021 Share Options to trading on the regulated market of Euronext Brussels (or such other markets on which the Company's shares will be trading at that time);

- (h) Waiver: The general shareholders' meeting acknowledges that the 2021 Share Options to be granted under the "2021 Share Option Plan" shall not be considered "variable remuneration", "fixed remuneration" or "annual remuneration" within the meaning of the Belgian Companies and Associations Code (including for, but not limited to, the purposes of Articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Corporate Governance Code (including for, but not limited to, the purposes of provision 7.11 of the 2020 Corporate Governance Code). In accordance with Article 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies and Associations Code, the general shareholders' meetings approves the vesting conditions and mechanisms of the 2021 Share Options, as included in the Plan; and
- (i) Approval in accordance with Article 7:151 of the Belgian Companies and Associations Code: The general shareholders' meeting resolves to take note, approve and ratify, insofar as required in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of Article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders' meeting grants a special power of attorney to each Director of the Company, notary public Dirk Delbaere, and to Fin-2K BV, represented by Kirsten Van Bockstaele (*Chief Financial Officer*), each acting alone and with power of substitution, for the purpose of carrying out the formalities required by Article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.

Attendance quorum: According to the Belgian Companies and Associations Code, an attendance quorum of at least 50% of the outstanding shares must be present or represented at the extraordinary general shareholders' meeting for the deliberation and voting on the agenda items of the aforementioned agenda of the extraordinary general shareholders' meeting. If such attendance quorum is not reached, a second extraordinary general shareholders' meeting will be convened for these agenda items, unless, as the case may be, decided otherwise on behalf of the Board of Directors, and the attendance quorum requirement will not apply to such second meeting.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned agenda of the extraordinary general shareholders' meeting shall be passed if they are approved by a majority of

75% of the votes validly cast by the shareholders. Pursuant to Article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the extraordinary general shareholders' meeting, but only with an advisory vote.

PARTICIPATION TO THE MEETINGS

Introduction: Holders of securities issued by the Company that wish to participate to the ordinary and extraordinary general shareholders' meetings of the Company should take into account the formalities and procedures described below.

Registration date: The registration date for ordinary and extraordinary general shareholders' meetings shall be Thursday 13 May 2021, at midnight (12:00 a.m., Belgian time). Only persons owning securities issued by the Company on Thursday 13 May 2021, at midnight (12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at the ordinary and extraordinary general shareholders' meetings. Only shareholders are entitled to vote. The holders of subscription rights can participate to the ordinary and extraordinary general shareholders' meetings but only with an advisory vote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are described under "—Participation to the meetings".

Participation to the meetings: In order to be able to participate to the ordinary and extraordinary general shareholders' meetings, a holder of securities issued by the Company must satisfy two conditions: (i) be registered as holder of such securities on the registration date, and (ii) notify the Company, as described below:

- (i) **Registration:** Firstly, the right for a holder of securities issued by the Company to participate to and, as applicable, to vote at the ordinary and extraordinary general shareholders' meetings is only granted on the basis of the registration of the securities concerned on the aforementioned registration date at midnight, via registration, in the applicable register book for the securities concerned (for registered securities) or in the accounts of a certified account holder or the relevant settlement institution for the securities concerned (for dematerialised securities).
- (ii) **Notification:** Secondly, in order to participate to the ordinary and extraordinary general shareholders' meetings, the holders of securities issued by the Company must notify the Company whether they want to participate to the meetings and must do so prior to or at the latest on Friday, 21 May 2021. The holders of securities who wish to make such notification can make use of the registration notice form that can be obtained at the Company's registered office and on the Company's website (www.sequanamedical.com). The notice must reach the Company by mail at its registered office (AA Tower, Technologiepark 122, 9052 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail at IR@sequanamedical.com at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders' meetings, *i.e.*, on or before Friday, 21 May 2021 at the latest. For the holders of dematerialised securities, the notification should include a certificate confirming the number of securities that have been registered in their name on the registration date. The certificate can be obtained by the holders of the dematerialised securities with the certified account holder, the relevant settlement institution, or the relevant financial intermediary for the securities concerned.

Voting by mail: The shareholders can vote by mail in accordance with Article 37 of the Company's Articles of Association. Votes by mail must be cast by means of the form prepared by the Company. The voting by mail form can be obtained on the Company's website (www.sequanamedical.com). The voting by mail form must be signed in handwriting or electronically. If the possibility to sign the voting by mail form electronically is used, it must be an electronic signature within the meaning of Article 3.10 of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal

market and repealing Directive 1999/93/EC, as amended, or a qualified electronic signature within the meaning of Article 3.12 of the same Regulation. Signed voting by mail forms must reach the Company by mail at its registered office (AA Tower, Technologiepark 122, 9052 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail accompanied by a scanned or photographed copy of the voting by mail form at IR@sequanamedical.com, at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders' meetings, *i.e.*, on or before Friday, 21 May 2021 at the latest. Holders of securities who wish to vote by mail must in any case comply with the formalities to participate to the meetings as explained under "—Participation to the meetings".

Representation by proxy: The holders of securities can participate to the meetings and vote, as applicable, through a handwritten proxy, as the case may be, to the Chairman of the Board of Directors. The written proxy must contain specific voting instructions for each proposed resolution. Proxy forms can be obtained on the Company's website (www.sequanamedical.com). The proxy must be signed in handwriting or electronically. The electronic signature must meet the same requirements as the electronic signature for the voting by mail form (see also "—Voting by mail"). Signed proxies must reach the Company by mail at its registered office (AA Tower, Technologiepark 122, 9052 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail accompanied by a scanned or photographed copy of the proxy form at IR@sequanamedical.com, at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders' meetings, *i.e.*, on or before Friday, 21 May 2021 at the latest. The appointment of a proxy holder must be made in accordance with the applicable rules of Belgian law, including in relation to conflicts of interests and the keeping of a register. Holders of securities who wish to be represented by proxy must, in any case comply with the formalities to participate to the meetings, as explained under "—Participation to the meetings".

Amendments to the agenda and additional proposed resolutions: Shareholders who alone or together with other shareholders hold at least 3% of the share capital of the Company have the right to put additional items on the agenda of the ordinary and extraordinary general shareholders' meetings and to table draft resolutions in relation to items that have been or are to be included in the agenda. If the required attendance quorum for the items on the agenda of the extraordinary general shareholders' meeting is not reached and a second extraordinary general shareholders' meeting is convened to deliberate and vote on such items, this right will not apply in relation to the agenda of the second extraordinary general shareholders' meeting. Shareholders wishing to exercise this right must prove on the date of their request that they own at least 3% of the outstanding shares. The ownership must be based, for dematerialised shares, on a certificate issued by the relevant settlement institution for the shares concerned, or by a certified account holder, confirming the number of shares that have been registered in the name of the relevant shareholders, and, for registered shares, on a certificate of registration of the relevant shares in the share register book of the Company. In addition, the shareholders concerned must, in any case, comply with the formalities to participate to the meetings, as explained under "—Participation to the meetings", with at least 3% of the outstanding shares. A request to put additional items on the agenda and/or to table draft resolutions must be submitted in writing, and must contain, in the event of an additional agenda item, the text of the agenda item concerned and, in the event of a draft resolution, the text of the draft resolution. The request must also mention the mail or e-mail address to which the Company will send the confirmation of receipt of the request. The request must reach the Company by mail at its registered office (AA Tower, Technologiepark 122, 9052 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail at IR@sequanamedical.com at the latest on the twenty-second calendar day prior to the ordinary and extraordinary general shareholders' meetings, *i.e.*, on or before Wednesday, 5 May 2021 at the latest. In case of amendments to the agenda and additional proposed resolutions as aforementioned, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional proposed resolutions no later than on the fifteenth calendar day prior to the ordinary and extraordinary general shareholders' meetings, *i.e.*, on or before Wednesday, 12 May 2021 at the latest. In addition, the Company shall make amended forms available for votes by mail and votes by proxy. Proxies and votes by mail that reach the Company prior to the publication of an

amended agenda remain valid for the agenda items to which the proxies and votes by mail apply, subject, however, to applicable law and the further clarifications set out on the proxy forms and vote by mail forms.

Right to ask questions: Each holder of securities issued by the Company has the right to ask questions to the Directors and the Statutory Auditor related to items on the agenda of a general shareholders' meeting. Questions can be asked during the meetings or can be submitted in writing prior to the meetings. Written questions must reach the Company by mail at its registered office (AA Tower, Technologiepark 122, 9052 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail at IR@sequanamedical.com at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders' meetings, *i.e.*, on or before Friday, 21 May 2021 at the latest. Answers to written questions will be provided in writing and will be published on the Company's website (www.sequanamedical.com) on or before Thursday, 27 May 2021 at the latest, but before the vote on items on the respective agendas of the meetings concerned in accordance with applicable law. Oral questions will be answered during the meetings concerned in accordance with applicable law. In addition, in order for written questions to be considered, the holders of securities issued by the Company who submitted the written questions concerned must comply with the formalities to participate to the meetings, as explained under "—Participation to the meetings" and/or under "—Voting by mail" or "—Representation by proxy".

Access to the meeting room: The natural persons who attend the ordinary and extraordinary general shareholders' meetings in their capacity as owner of securities, holder of proxies or representative of a legal entity must be able to provide evidence of their identity in order to be granted access to the meeting room (subject to what is shared above under "—*Exceptional circumstances*" in section "—*General information*"). In addition, the representatives of legal entities must hand over the documents establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start of the meetings.

Recommendation to use e-mail: As postal services may be disrupted due to the COVID-19 pandemic, the Company recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders' meetings. The Company's e-mail address for such communication is: IR@sequanamedical.com. The Company also points at that, in addition in addition to be physically available at the Company's registered office and distributed by mail, all forms and other documentation in relation to the general shareholders' meetings will be available on the Company's website (www.sequanamedical.com). See also "—Available documentation".

DATA PROTECTION

The Company is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and proxy holders in the context of general shareholders' meetings. The processing of such data will be carried out for the purposes of the organisation and conduct of the relevant general shareholders' meetings, including the convening notices, registrations, participation and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or services to the Company in connection with the foregoing. The processing of such data will be carried out, *mutatis mutandis*, in accordance with the Company's Privacy & Cookie Policy, available on the Company's website (<https://www.sequanamedical.com/privacy-cookie-policy>). The Company draws the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in the section 'Information regarding your rights' of the aforementioned Privacy & Cookie Policy. All this does not affect the rules that apply in connection with the registration and participation to the general shareholders' meetings. To exercise rights as a data subject and for all other information

regarding the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@sequanamedical.com.

AVAILABLE DOCUMENTATION

The following documentation is available on the Company's website (<https://www.sequanamedical.com/investors/shareholder-information>): the notice convening the ordinary and extraordinary general shareholders' meetings, the agenda and proposed resolutions, or, if no resolutions are proposed, a commentary by the Board of Directors, an explanatory note on the agenda and proposed resolutions, updates of the agenda and proposed resolutions (in case of amendments to the agenda and proposed resolutions), the documents to be submitted to the ordinary and extraordinary general shareholders' meetings as referred to in the agenda of the meetings, the vote by mail forms, and the proxy forms. The aforementioned website also mentions the total number of outstanding shares and voting rights of the Company.

On behalf of the Board of Directors,

THIS DOCUMENT IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SHARES, SUBSCRIPTION RIGHTS OR OTHER SECURITIES OF SEQUANA MEDICAL NV. THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.